Skip to main content
Top
Published in:

Open Access 21-04-2025 | Parkinson Disease | Review

Keeping an eye on Parkinson’s disease: color vision and outer retinal thickness as simple and non-invasive biomarkers

Authors: Jingjing Lin, David I. Finkelstein, Andrew J. Anderson, Pei Ying Lee, Bang V. Bui, Tissa Wijeratne, Jane E. Alty, Christine T. O. Nguyen

Published in: Journal of Neurology | Issue 5/2025

Login to get access

Abstract

Over the last two decades, visual symptoms and retinal changes in Parkinson’s disease (PD) have emerged as important biomarkers. Color vision deficiency, which begins in the outer retina, has been increasingly investigated, but a focused review of these papers has not recently been conducted. Similarly, thinning of the outer retina as measured using optical coherence tomography (OCT) holds potential as a screening marker for PD, particularly as these devices are already commonplace in community and hospital settings. Moreover, outer retinal thinning may be more specific for Parkinson’s disease as inner retinal changes also occur in more common neurodegenerative diseases like glaucoma and Alzheimer’s disease. This review summarizes contemporary evidence on two outer retina focused measures, color vision and outer retinal thickness, which can be readily quantified using non-invasive approaches and thus examines their potential as biomarkers for screening, detection, and progression in PD.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
Keeping an eye on Parkinson’s disease: color vision and outer retinal thickness as simple and non-invasive biomarkers
Authors
Jingjing Lin
David I. Finkelstein
Andrew J. Anderson
Pei Ying Lee
Bang V. Bui
Tissa Wijeratne
Jane E. Alty
Christine T. O. Nguyen
Publication date
21-04-2025
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 5/2025
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-025-13080-6

How can your team use biomarkers to improve management of AD? (Link opens in a new window)

Our experts explore using biomarker tests and interpreting results, establishing a shared decision-making approach with patients and caregivers, and applying biomarker testing to guide treatment strategies.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Healthcare IME
Register your interest

How can you integrate PET into your practice? (Link opens in a new window)

1.5 AMA PRA Category 1 Credit(s)™

PET imaging is playing an increasingly critical role in managing AD. Our expert-led program will empower you with practical strategies and real-world case studies to effectively integrate it into clinical practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Healthcare IME
Register your interest